CA3136328A1 - Prophylactic efficacy of serotonin 4 receptor agonists against stress - Google Patents

Prophylactic efficacy of serotonin 4 receptor agonists against stress Download PDF

Info

Publication number
CA3136328A1
CA3136328A1 CA3136328A CA3136328A CA3136328A1 CA 3136328 A1 CA3136328 A1 CA 3136328A1 CA 3136328 A CA3136328 A CA 3136328A CA 3136328 A CA3136328 A CA 3136328A CA 3136328 A1 CA3136328 A1 CA 3136328A1
Authority
CA
Canada
Prior art keywords
stress
mice
administered
ht4r
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136328A
Other languages
English (en)
French (fr)
Inventor
Christine A. DENNY
Alain M. GARDIER
Denis J. DAVID
Indira MENDEZ-DAVID
Charlene Faye
Briana K. CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Columbia University
Research Foundation For Mental Hygiene
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Columbia University
Research Foundation For Mental Hygiene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Columbia University, Research Foundation For Mental Hygiene filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of CA3136328A1 publication Critical patent/CA3136328A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3136328A 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress Pending CA3136328A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962831517P 2019-04-09 2019-04-09
US62/831,517 2019-04-09
US201962857075P 2019-06-04 2019-06-04
US62/857,075 2019-06-04
US201962910859P 2019-10-04 2019-10-04
US62/910,859 2019-10-04
PCT/US2020/027321 WO2020210393A1 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Publications (1)

Publication Number Publication Date
CA3136328A1 true CA3136328A1 (en) 2020-10-15

Family

ID=72750568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136328A Pending CA3136328A1 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Country Status (8)

Country Link
US (1) US20220031684A1 (enExample)
EP (1) EP3952852B1 (enExample)
JP (1) JP7683882B2 (enExample)
CN (1) CN113924087A (enExample)
AU (1) AU2020271839B2 (enExample)
CA (1) CA3136328A1 (enExample)
MX (1) MX2021012394A (enExample)
WO (1) WO2020210393A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821116B2 (ja) * 2020-04-07 2026-02-26 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
EP4577305A4 (en) * 2022-08-25 2026-07-29 Univ Columbia COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ANOTHER NEURODEGENERATIVE DISEASE
CN118105081B (zh) * 2024-03-04 2025-02-11 天津大学 一种情绪状态与神经电生理状态调节装置、验证系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20090170899A1 (en) 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Also Published As

Publication number Publication date
MX2021012394A (es) 2022-01-19
JP2022527865A (ja) 2022-06-06
EP3952852B1 (en) 2026-07-22
AU2020271839B2 (en) 2025-04-24
WO2020210393A1 (en) 2020-10-15
EP3952852A4 (en) 2023-01-04
AU2020271839A1 (en) 2021-11-04
CN113924087A (zh) 2022-01-11
US20220031684A1 (en) 2022-02-03
JP7683882B2 (ja) 2025-05-27
EP3952852A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
Petroianu et al. Neuropathic pain: Mechanisms and therapeutic strategies
US11110070B2 (en) Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
Mitchell et al. Good night and good luck: norepinephrine in sleep pharmacology
US12239614B2 (en) Pharmacological prophylactics against stress-induced affective disorders in females
US20220031684A1 (en) Prophylactic efficacy of serotonin 4 receptor agonists against stress
JP7821116B2 (ja) ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
Buran et al. Treatment with TREK1 and TRPC3/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress
KR20100059830A (ko) 도파민 수용체 리간드를 함유하는 약학적 조성물 및 도파민 수용체 리간드를 사용한 치료 방법
US20220071932A1 (en) Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms
US20090082341A1 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
Abd-Elsayed et al. Selective NaV1. 8 inhibition for pain management: current evidence and future potential of suzetrigine
US9517265B2 (en) Methods for the prevention and/or treatment of memory impairment
US20200316087A1 (en) Novel combination therapy for anxiety disorders, epilepsy, and pain
Harun et al. The neurobiological basis of pharmacological approaches for patients with traumatic brain injury
WO2023215338A1 (en) Compositions and methods for treating cluster headache
WO2023215342A1 (en) Compositions and methods for treating trigeminal neuralgia
Brandt Critical review report: 3-Methylmethcathinone (3-MMC)
Di Martino et al. Cannabidiol for the Treatment of Neurodevelopmental Disorders: Focus on Schizophrenia and Autism
Davis et al. Therapeutic goals for the management of posttraumatic stress disorder (PTSD) most commonly innightmares, intrusive irrita
Davis et al. Therapeutic goals for the management commonly innightmares
Cameron Psychedelics and novel non-hallucinogenic analogs for treating neuropsychiatric disorders
Linge Méndez et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Shaw et al. Psychopharmacology in the physically ill child
Cruz Impact of Psychoactive Drugs on Mental Health
Posner Novel melatonin MT1 receptor agonists as antidepressants: In vivo electrophysiological and behavioural characterization

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240321

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250328

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250725

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250731

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250818

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250818

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20251118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260403

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260602